ReviewThe Korean journal of internal medicine2013
Molecular targeted therapy for advanced gastric cancer.
Review in The Korean journal of internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular-targeted first-line therapy for advanced gastric cancer.The Cochrane database of systematic reviews · 2016Pooled it
- Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.World journal of gastrointestinal oncology · 2024Review
- Review
- Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.World journal of gastroenterology · 2016Review
- Upregulation of microRNA-31 targeting integrin α5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Emerging molecular classifications and therapeutic implications for gastric cancer.Chinese journal of cancer · 2016Review
- HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients.Oncology letters · 2016Article
- Thyroid carcinoma cells produce PLGF to enhance metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Molecular regulation of cervical cancer growth and invasion by VEGFa.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- PLGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Glucose-regulated protein 78 and heparanase expression in oral squamous cell carcinoma: correlations and prognostic significance.World journal of surgical oncology · 2014Article
- The progress of targeted therapy in advanced gastric cancer.Biomarker research · 2013Article
- Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer.Current oncology (Toronto, Ont.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although medical treatment has been shown to improve quality of life and prolong survival, no significant progress has been made in the treatment of advanced gastric cancer (AGC) within the last two decades. Thus, the optimum standard first-line chemotherapy regimen for AGC remains debatable, and most responses to chemotherapy are partial and of short duration; the median survival is approximately 7 to 11 months, and survival at 2 years is exceptionally > 10%. Recently, remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways. For AGC, many molecular targeting agents have been evaluated in international randomized studies, and trastuzumab, an anti-HER-2 monoclonal antibody, has shown antitumor activity against HER-2-positive AGC. However, this benefit is limited to only ~20% of patients with AGC (patients with HER-2-positive AGC). Therefore, there remains a critical need for both the development of more effective agents and the identification of molecular predictive and prognostic markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.